Le Lézard
Classified in: Covid-19 virus
Subject: Nonprofit

Patients Suffer as Pfizer Pockets Profits, says AHF


The AIDS Healthcare Foundation (AHF) rebuked pharmaceutical giant Pfizer today for announcing that it plans to charge $1,400 for a five-day course of the COVID-19 antiviral drug Paxlovid. During the pandemic, the U.S. government only paid $529 for the same drug.

"This is yet another example of rampant drug profiteering off the backs of sick people by Big Pharma. The same drug, with the same efficacy, will suddenly cost nearly three times as much when it reaches the commercial market. Why? So that Pfizer can squeeze as much money out of health plans and the pockets of the uninsured as possible for its shareholders and executives," said AHF President Michael Weinstein. "Greedy Pfizer is in good company ? Gilead charges $3,429 for its five-day COVID-19 treatment. We must prioritize public health and equity over corporate profits. Putting profits before people's lives and health is not only immoral, it leaves the entire world in danger of another pandemic disaster."

Pfizer's Paxlovid and Gilead's Remdesivir are particularly beneficial for people at a higher risk of developing complications from a COVID-19 infection. These patients are already likely to face higher treatment costs due to hospitalizations and prolonged treatment and recovery periods. The exorbitant prices of these drugs put further strain on the personal finances of affected people and healthcare systems, which are still recovering from the effects of the pandemic.

About AIDS Healthcare Foundation (AHF)

AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to over 1.9 million people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare


These press releases may also interest you

at 08:00
YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

at 08:00
Today, Valens Semiconductor , a leader in high-performance connectivity, and Black Sesame Technologies, a leading intelligent vehicle SoC and solution provider, announced that they have worked together to enable the integration of A-PHY connectivity...

at 08:00
Oshi Health, the virtual digestive health center of excellence, today announced that two virtual care pioneers have joined the company and its mission: Martin Anderson as Chief Technology Officer and Nathan Paulsen as VP of Health Plan Partnerships....

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference ? May 14-15, 2024 Type: Fireside Chat Presentation Date/Time: May 14,...

at 07:30
New Pacific Metals Corp. ("New Pacific" or the "Company") is pleased to announce the positive results of its metallurgical test program for its Silver Sand project ("Silver Sand") located in Potosi Department, Bolivia. The test program was...

at 07:30
Guanajuato Silver Company Ltd. (the "Company" or "GSilver") is pleased to announce an upsizing of its previously announced brokered, best-efforts offering ("Offering") for an additional C$2,250,000 under a private...



News published on and distributed by: